SCHEMBL10070528

SCHEMBL10070528

C=CCOc1c(Br)cc(C2C(C(=O)OCC)=C(N)Oc3cc4c(cc32)OCO4)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
MAPT P10636 5/20 0.46
TSHR P16473 3/20 0.46
KDM4E B2RXH2 3/20 0.46
HSD17B10 Q99714 2/20 0.46
POLB P06746 2/20 0.46
CASP1 P29466 1/20 0.46
PAX8 Q06710 2/20 0.45
MITF O75030 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
TP53 P04637 1/20 0.44
GAA P10253 4/20 0.41
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
BLM P54132 1/20 0.39
RUNX1 Q01196 1/20 0.39
CBFB Q13951 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6014321 0.89 MEN1 (0.43) ALDH1A1MAPTKDM4EHSD17B10POLB
SCHEMBL15363880 0.87 MEN1 (0.47) ALDH1A1MAPTTSHRKDM4EHSD17B10
SCHEMBL5048290 0.82 HTT (0.70) ALDH1A1MAPTTSHRKDM4EHSD17B10
SCHEMBL4541461 0.79 MYB (0.61) MAPTKDM4EGAAHPGDSMN1; SMN2
SCHEMBL4542953 0.76 MEN1 (0.52) ALDH1A1MAPTTSHRHSD17B10HTT
SCHEMBL15363771 0.74 ALDH1A1 (0.47) ALDH1A1MAPTTSHRKDM4EHSD17B10
SCHEMBL6014322 0.71 MYB (0.56) ALDH1A1MAPTKDM4EHSD17B10POLB
SCHEMBL15370281 0.70 ESR1 (0.48) ALDH1A1MAPTTSHRHSD17B10HTT
SCHEMBL15363961 0.69 HTT (0.86) ALDH1A1MAPTTSHRKDM4EHSD17B10
SCHEMBL4325677 0.68 MAPT (0.66) ALDH1A1MAPTKDM4EHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2638025-B1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) 2020-02-05 EP disclosed
EP-2638025-B1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) 2020-02-05 EP disclosed
US-20180334442-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS Ruprecht-Karls-Universität Heidelberg (DE) 2018-11-22 US disclosed
US-10065939-B2 Chromene derivatives and their analogs as Wnt pathway antagonists DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2018-09-04 US disclosed
EP-2638026-B1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) 2018-07-11 EP disclosed
EP-2638026-B1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) 2018-07-11 EP disclosed
US-20160355496-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-12-08 US disclosed
US-20160355496-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-12-08 US disclosed
US-20160355496-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-12-08 US disclosed
US-9371333-B2 Chromene derivatives and their analoga as Wnt pathway antagonists DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-06-21 US disclosed
US-9371333-B2 Chromene derivatives and their analoga as Wnt pathway antagonists DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-06-21 US disclosed
US-9371333-B2 Chromene derivatives and their analoga as Wnt pathway antagonists DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-06-21 US disclosed
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-14 US disclosed
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-14 US disclosed
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-14 US disclosed
US-20130296344-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-07 US disclosed
US-20130296344-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-07 US disclosed
US-20130296344-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-07 US disclosed
WO-2012062905-A2 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A ALDH1A1 3782/4885MAPT 4364/4885TSHR 711/4885
US-20160355496-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A ALDH1A1 4092/4885MAPT 4492/4885TSHR 888/4885
US-10065939-B2 Chromene derivatives and their analogs as Wnt pathway antagonists WNT3, WNT1, WNT3A ALDH1A1 4092/4885MAPT 4492/4885TSHR 888/4885
US-20130296344-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A ALDH1A1 3312/4885MAPT 4559/4885TSHR 811/4885
US-20180334442-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A ALDH1A1 4092/4885MAPT 4492/4885TSHR 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.